ClinicalTrials.gg
RecruitingNCT05952674DepVNSUpdated Jun 23, 2026

Treatment Resistant Depression and Vagus Nerve Stimulation

An interventional study of Vagus Nerve Stimulation (VNS) and Best Medical Treatment in Treatment Resistant Depression (TRD), sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 24 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Depressive Disorder, Treatment-Resistant with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Depressive Disorder, Treatment-Resistant · France.

Planned enrollment
8th of 21
166 · median 119
Started
2024
with 3 others
No phase
14 of 23
6 open now
Registered
12th of 23
by date
Lead sponsor
2 of 23
Assistance Publique - Hôpitaux de Paris

Among the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France, this one is the 8th largest by planned enrollment of the 21 interventional ones that give a count, is one of 4 that started in 2024, is one of 14 with no phase, and was the 12th registered.

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

9 of the 23 studies in Depressive Disorder, Treatment-Resistant with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Depressive Disorder, Treatment-Resistant with a site in France, or all of them as a file.
02

Study summary

Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide.

Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption.

Sometimes, TRD is part of a bipolar illness. In this case, the challenge is even bigger because antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients.

The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response.

The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry.

The DepVNS hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment.

The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.

Read the detailed description

Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments. Despite the optimization of antidepressant medical strategies, 20 to 40% of depressions do not respond to treatment. This is particularly worrying as 6% of non-responder patients will die by committing suicide. The term treatment-resistant depression (TRD) is used when two or more (and often many more) well conducted antidepressant treatments from different classes have failed to achieve remission.

Depression has a major impact on quality of life, socio-professional functioning and healthcare consumption. According to the World Health Organization (WHO), depression will be the second cause of healthcare costs in the world by 2020. RD alone accounts for 30 to 40% of the annual cost of depression.

Sometimes, TRD is part of a bipolar illness, a psychiatric condition characterized by the alternation of depressive and maniac episodes that affects 4% of the population. In this case, the challenge is even bigger because (1) antidepressants are no well tolerated, further reducing the therapeutic options in case of resistance, (2) the severity and duration of the depressive episodes are the main factors explaining the deterioration of the quality of life and the increasing cost of cares for these patients. Bipolar RD currently accounts for 20% of all psychiatric spending.

The standard treatment for TRD is electroconvulsive therapy (ECT), which results in a response in 60 to 70% of cases after a few weeks of treatment. However, the improvement is often transient and 40% of patients relapse within 6 months of the initial ECT session. Moreover, ECT is often not well tolerated because of the frequency and the intensity of the memory disorders associated, the repetition of anesthesia and hospitalizations and its social stigma. Refusals and requests to stop ECT are therefore common even when it is effective, as these constraints are sometimes experienced as being unbearable in the long-term. This therapeutic impasse therefore makes TRD a priority public health target to which it is urgent to provide a realistic medico-economical response.

The literature suggests that Vagus Nerve Stimulation (VNS) has unique kinetics of efficacy in depression, particularly in preventing the long-term recurrences, and therefore responding to the lack of effective maintenance treatment in TRD. In fact, the benefits of VNS gradually accumulate over 12-24 months, which makes it complementary to more incisive treatments like ECT. Finally, its efficacy-tolerance profile appears to be similar in uni and bipolar TRD, giving VNS a potentially unique place in the therapeutic arsenal in psychiatry. VNS has been approved for over 15 years as a treatment for RD in the Unites States and Great-Britain.

The hypothesis is that VNS is a medico-economically efficient therapeutic option to overcome the therapeutic impasse in which patients suffering from uni and bipolar DR currently find themselves due to the frequency of relapses under treatment.

The primary objective is to estimate, from a collective point of view, the incremental cost-utility ratio of VNS to treat patients suffering from RD.

The secondary objectives are evaluating the efficacy and the security of the VNS, as well as positioning the VNS in comparison with ECT that is currently the standard treatment for TRD.

This is a national multicenter comparative, open, randomized, controlled, two-parallel group clinical trial evaluating the medico-economic impact of VNS in resistant depression population. Patients (166) suffering from resistant depression will be enrolled over a 24-month period and will be randomized in a (1:1) ratio to receive either Vagus Nerve Stimulation (VNS) along with the Best Medical Treatment (VNS+BMT arm) or the Optimal Medical Treatment only (BMT arm).

Patients meeting all eligibility criteria will be enrolled in the study.

All subjects will be followed by the investigators or designee of the investigator during the whole study period by visits on site.

Number of visits/participant: Both arms will attend: selection visit (VS), inclusion visit (VI) and randomization visit (R), M0, M2, M4, M6, M8, M10, M12, M14, M16, M18, M20, M22 and M24. After the inclusion visit, the experimental arm (VNS + BMT) will further attend a neurosurgical and anesthetic consultation before being hospitalized for the VNS system placement. The patient will finally be hospitalized in psychiatry for about 5 days for switching the device on. If the target intensity has not been reached during this hospitalization, an adjustment visit is planned every month for 6 months in order to progressively increase the stimulation intensity until the target or a therapeutic response. If the target or the therapeutic response is obtained, the settings adjustments rhythm will be at the indiscretion of the psychiatrist. If at the end of the 6 first visits (M1 to M6), the target intensity couldn't be reached or in absence of a satisfying clinical response, a visit will be planned every 3 months (consultation or hospitalization) to keep optimizing the VNS.

03

Conditions studied

  • Treatment Resistant Depression (TRD)

Keywords

  • Treatment Resistant Depression (TRD)
  • Vagus Nerve Stimulation (VNS)
  • Best Medical Treatment (BMT)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years and older ;
  • Childbearing women must have an efficient for the whole study period
  • Diagnosis of recurrent depressive trouble or persistent depressive disorder or bipolar disorder (according to )
  • Start of disorder (defined by the occurrence of the first thymus episode: characterized depressive disorder or maniac episode with or without mixed characteristics) for 5 years or more
  • At least one of the following criteria:

    • Criterion A: current characterized depressive disorder and characterized depressive disorder for at least 12 months during the last 24 months despite at least four treatments lines at appropriate dosage and duration
    • Criterion B: current treatment by ECT/(Es)Ketamine/TMS and criteria A before the start treatment or ECT/(Es)Ketamine/TMS dependency
  • Patients who, after the nature of the study has been explained to them, have given written consent

Exclusion criteria

Exclusion Criteria:

  • Know pregnancy or breastfeeding
  • Schizophrenia, schizoaffective disorder or persistent delusional disorder ()
  • Characterized depressive disorder with psychotic characteristics within 3 months before the inclusion (DSM-5)
  • Concomitant participation to another interventional research not authorized by the coordinating investigator or the scientific lead. Participation to non-interventional researches is allowed.
  • Patients receiving enforced cares (ASPDT, ASPPI, ASPDRE, etc.)
  • Non-affiliation to a social security regimen or any other social protection regimen
  • Disability, according to the investigator, to understand the study or refusal to sign the study consent form (non-francophone patient, cognitive disorders)
  • Anticipated disability to attend all the visits, treatments and measures planned by the protocol: severe personality disorder, severe substance addiction, severe intellectual development disorder. In any of those cases, the notion of severity is at the indiscretion of the investigator

Secondary Exclusion Criteria:

  • Surgical to the VNS
  • Positive β-HCG (results obtained after the is signed but before the randomization)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
166 participants (estimated)

Study arms

  • Experimental
    Vagus Nerve Stimulation (VNS) + Best Medical Treatment (BMT)

    Along with the Optimal Medical Treatment for resistant depression, the VNS + BMT arm will be implanted a medical device of VNS.

    Device: Vagus Nerve Stimulation (VNS)

  • Active comparator
    Best Medical Treatment

    The BMT arm will only receive the Optimal Medical Treatment for resistant depression.

    Other: Best Medical Treatment

Interventions

  • DeviceVagus Nerve Stimulation (VNS)

    The surgical intervention for the implantation of the VNS medical device is performed by a neurosurgeon under general anesthesia and lasts about an hour. Two incisions are made on the left: one incision to implant an electrode wrapped around the vagus nerve, the other incision to implant the stimulator. The electrode and the stimulator are connected by a cable tunneled. The cardiac tolerance is usually tested at the end of the surgery by turning on the neurostimulator for a few minutes. The stimulator is turned on about two weeks after the implantation, and after the neurosurgeon has checked the quality of healing. The settings used in first intention are standardized and derived from the parameters usually used for the treatment of epilepsies: a pulse width of 250μs, a stimulation frequency of 30Hz, and a 30sec stimulation cycle (ON) every 5min (OFF). Intensity is progressively increased by steps of 0.25mA to reach the 1.5-2mA range, depending on stimulation-induced side effects.

  • OtherBest Medical Treatment

    Best Medical Treatment for resistant depression.

06

What researchers measure

Primary outcomes

  1. Cost-utility of VNS

    Incremental cost-utility ratio of the Vagus Nerve Stimulation (group VNS + optimal medical treatment) in comparison to the control group (optimal medical treatment only) within 24 months of VNS placement

    Time frame: Month 24

Secondary outcomes

  1. Efficacy of the VNS

    Response rate (\< 50% amelioration of the QIDS-SR baseline score) cumulative and non-cumulative

    Time frame: Month 24

  2. Efficacy of the VNS

    Remission rate (QIDS-SR score ≤ 5) cumulative and non cumulative

    Time frame: Month 24

  3. Efficacy of the VNS

    CGI (Clinical Global Impression). Three scores: severity of the disease noted out of 7, overall improvement noted out of 7 and therapeutic index noted out of 16.

    Time frame: Month 24

  4. Efficacy of the VNS

    EGF (Functioning Global Evaluation scale). Minimum: 0. Maximum: 100. The higher the score, the higher the level of psychological, social and occupational functioning.

    Time frame: Month 24

  5. Efficacy of the VNS

    Number of weeks in depression, remission, (hypo)mania and number of major depressive episodes and (hypo)maniac episodes (DSM-5 criteria)

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  6. Efficacy of the VNS

    Average intensity of anxious symptoms : STAI-A (State-Trait Anxiety Inventory - Form A). Minimum: 20. Maximum: 80. A higher score indicates greater anxiety.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  7. Efficacy of the VNS

    Average intensity of thymus symptoms : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  8. Efficacy of the VNS

    Average intensity of thymus symptoms : YMRS (Young Mania Rating Scale). Minimum: 0. Maximum: 60. The higher the score, the more severe the symptoms.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  9. Efficacy of the VNS

    Average intensity of thymus symptoms : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  10. Efficacy of the VNS

    Average intensity of thymus symptoms : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  11. Efficacy of the VNS

    Average intensity of depressive episodes : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  12. Efficacy of the VNS

    Average intensity of depressive episodes : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  13. Efficacy of the VNS

    Average intensity of depressive episodes : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  14. Efficacy of the VNS

    Average duration of response periods (\< 50% improvement in QIDS-SR baseline score).

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  15. Efficacy of the VNS

    Average intensity of symptoms during the response phases : QIDS-SR (Quick Inventory of Depressive Symptomatology - Self Report). Minimum: 0. Maximum: 27. The higher the score, the worse the symptoms.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  16. Efficacy of the VNS

    Average intensity of symptoms during the response phases : VAS mood (Visual Analogue Scale Mood). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  17. Efficacy of the VNS

    Average intensity of symptoms during the response phases : VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  18. Efficacy of the VNS

    Average intensity of (hypo)maniac episodes: YMRS (Young Mania Rating Scale). Minimum: 0. Maximum: 60. The higher the score, the more severe the symptoms.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  19. Efficacy of the VNS

    Average intensity of (hypo)manic episodes: VAS mood (Visual Analogue Scale Mood ). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his mood.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  20. Efficacy of the VNS

    Average intensity of (hypo)manic episodes: VAS motivation (Visual Analogue Scale Motivation). Cursor to be positioned by the patient on a non-graduated figure in order to reflect his motivation.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  21. Efficacy of the VNS

    Average duration of depressive episodes (DSM-5 criteria) and (hypo)manic episodes

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  22. Efficacy of the VNS

    Interval between the major depressive episodes and interval between the (hypo)maniac episodes (DSM-5 criteria)

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  23. Efficacy of the VNS

    Number of treatments/month

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  24. Efficacy of the VNS

    Total cost of cares

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  25. Efficacy of the VNS

    Quality of life : Q-LES-Q-SF (Quality of Life Enjoyment and Satisfaction Questionnaire Short Form). Score out of 70 and percentage. The higher the score, the higher the quality of life.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  26. Efficacy of the VNS

    Quality of life : SF-36 (Short Form 36 Health Survey). 8 dimensions each evaluated out of 100. The higher the score, the higher the quality of life.

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  27. Efficacy of the VNS

    Response rate (\< 50% improvement in QIDS-C baseline score) cumulative and non-cumulative

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  28. Efficacy of the VNS

    Average C-SSRS scoring

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  29. Impact of the VNS on ECT (electroconvulsive therapy)

    Cumulative number of ECT session within 24 months

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  30. Impact of the VNS on ECT (electroconvulsive therapy)

    Number of maintenance ECT session within 24 months

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  31. Impact of the VNS on ECT (electroconvulsive therapy)

    Average duration to obtain a complete ECT withdrawal

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  32. Impact of the VNS on ECT (electroconvulsive therapy)

    Average time period between ECT during the maintenance phase

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  33. Impact of the VNS on ECT (electroconvulsive therapy)

    Proportion of patients withdraw from ECT

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  34. Impact of the VNS on ECT (electroconvulsive therapy)

    Number of treatments per year

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  35. Impact of the VNS on ECT (electroconvulsive therapy)

    Results of EVA memory disorders severity

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

  36. Impact of the VNS on ECT (electroconvulsive therapy)

    Montreal Cognitive Assessment (MoCA) scoring

    Time frame: Months: 0, 12, 24

  37. Security of the VNS

    1/ VNS failure rate with a subgroup analysis for patients concomitantly treated by ECT, 2/Reported serious and non-serious adverse events

    Time frame: Months: 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24

07

Study locations

14 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Datas are own by Assistance Publique - Hôpitaux de Paris, please contact sponsor for further information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2031, 84 months after the start.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 84 months is above that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2021
First posted
Jul 19, 2023
StartActual
Feb 19, 2024
Primary completionEst.
Feb 26, 2031
CompletionEst.
Feb 19, 2033
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05952674
Collaborators
LivaNova
Responsible party
Sponsor
First posted
Jul 19, 2023
Start date
Feb 19, 2024
Primary completion
Feb 26, 2031 (estimated)
Completion
Feb 19, 2033 (estimated)
Last update
Jun 23, 2026

Study contacts

Philippe DOMENECH, MD, MSc
Contact
philippe.domenech@ghu-paris.fr
(0) 1 45 65 76 65 ext. +(33)
Fabien VINCKIER, MD, MSc
Contact
f.vinckier@ghu-paris.fr
(0) 1 45 65 84 52 ext. +(33)
Philippe DOMENECH, MD, MSc
study director · GHU Paris Psychiatrie & Neurosciences (site Sainte-Anne)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion